Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use for “the treatment of myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene rearrangements".
-
Clinical Benefit
Substantial
The actual benefit of Glivec is substantial.
Clinical Added Value
moderate
GLIVEC provides a moderate improvement in actual benefit (IAB III) in terms of efficacy as compared with the usual management of myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangement.